EN DE
Watch Facephi Biometria SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Facephi Biometria SA (FACE) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Facephi Biometria SA stock €1.00, price €1.75, that is 42.9% below the price, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Technology ES · ISIN ES0105029005

FB Facephi Biometria SA logo Some data Nov 9, 2026

Facephi Biometria SA

FACE · MC
Very expensive, weak quality

Our calculation puts a fair price 43% below what the stock costs today.

Low debt
Revenue last quarter +32% vs. a year ago.
Quality 40/100
Expensive Growth (revenue 5y +37.7 %/yr in EUR)
Thin margins · 0.8% net margin (TTM)
Some data
Fair value €1.00 · Strongly overvalued
Negative free cash flow
Trails peers (5/13)
Narrow moat 40/100 · thin data
Watch Facephi Biometria SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€5.02 €1.42 Fair Value €1.00 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range €1.42 – €5.02 · fair‑value band €0.8300 – €1.15 · the €1.75 price screens above the €1.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.

Follow Facephi Biometria in your weekly email

Every Wednesday you see whether Facephi Biometria is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Facephi Biometria, S.A. engages in the biometric facial recognition technology solutions in Spain and internationally.

Show moreShow less

The company offers authentication, a solution allows user to authenticate through multibiometric technology and prevents unauthorized access; onboarding, a solution that allows to verify the identity of users remotely, automatically capturing the document information, and taking a selfie with passive liveness; and digital identity platform, that allows the customer to design any digital onboarding and authentication process that allows the customer to design any digital onboarding and authentication process.

It also provides behavioural biometrics, an intelligent fraud detection solution; mule account detection for proactive protection against financial fraud; and Teseo ID wallet to manage verifiable credentials.

Its solutions are used in banking, fintech, crypto, insurance, gaming and gambling, aviation, hospitality, shared mobility, government, telcos, health industries. Facephi Biometria, S.A. was incorporated in 2012 and is headquartered in Alicante, Spain.

Stock analysis

Facephi Biometria SA (FACE) currently trades at €1.75, while our model-based Fair Value estimate is €1.00, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of €1.67 per share, and 2 of the 14 models we run sit above the €1.75 price.

Bear case: the Earnings-Based group reads lowest at €0.5750, and 12 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: €0.8300 (bear) to €1.15 (bull), the price of €1.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Technology sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Facephi Biometria SA reported revenue of €36.0M in FY2025 versus €13.2M in FY2021, a compound +28.6%/yr. Reported net income was €369K in FY2025.

Key figures

Market cap €46.3M Micro · P/E ratio 125.9 · P/S ratio 0.82 · EPS (TTM) €0.0139 · Net margin 0.8% · Return on equity 1.6% · Return on assets (EBIT) −3.1% (5-year average) · Operating margin 20.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Technology peers we cover trades at 10% fair-value upside, at −43%, FACE screens richer than that median.

Fair Value models

Bear €0.8300 Fair Value €1.00 Bull €1.15
Price €1.75 · Downside -42.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0086 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV €0.8300 €0.9000 €0.9700 74
ROIC Compounder €0.8300 €1.00 €1.15 70
Residual Income €0.4000 €0.4300 €0.4800 68
All 14 models by family
Earnings-Based
Graham-Dodd €0.0900 €0.6600 €0.9300 61
Lynch FV €0.3400 €0.4900 €0.6300 59
PEG = 1.0 €0.3400 €0.4900 €0.6300 55
EPV €0.8300 €0.9000 €0.9700 74
Multiples
P/E Multiple €0.2900 €0.3900 €0.4900 63
P/S Multiple €0.1800 €0.2400 €0.3000 58
P/B Multiple €1.31 €1.75 €2.19 55
EV/EBIT €2.27 €3.09 €3.91 66
EV/EBITDA €5.11 €6.88 €8.65 67
EV/Revenue €1.05 €1.58 €2.12 53
Asset-Based
NCAV (Graham) €0.0500 €0.0700 €0.0900 55
Economic Profit
Residual Income €0.4000 €0.4300 €0.4800 68
ROIC Compounder €0.8300 €1.00 €1.15 70
Growth Earnings
Growth-Adj P/E €0.4900 €0.7000 €0.9200 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 39
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 44
Do the profits arrive as real cash?
Financial strength 44
Debt, balance sheet and risk of trouble
Investment 22
Does it invest with discipline instead of growing at any price?
Low Volatility 42
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+24.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.7%
Start year 2020 (pandemic). Over 10 years: +56.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+100.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−32.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−32.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 10%

FACE screens overvalued: fair value 43% below the price. Compare with SAP SE →

Compare Facephi Biometria SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Application · 628 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −42.9% · Below median
Profitability
Return on equity (12 months) 1.6% · Below median
Return on assets 0.8% · Below median
Net margin (12 months) 0.8% · Below median
Operating margin (12 months) 20.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 32.0% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Software - Application median · lower = cheaper

P/E (12 months) 125.9× · Priciest 25%
P/B 2.37× · Pricier than median
P/S (12 months) 1.27× · Cheaper than median
EV/EBITDA 23.1× · Pricier than median
PEG 0.10× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 29
FUTURE (revenue growth)100 · sector 41
PAST (return on equity)6 · sector 20
HEALTH (low debt)99 · sector 98
DIVIDEND (yield)0 · sector 29

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Software - Application stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Adobe Inc ADBE $239.30 $463.72 +94% vs FACE
Salesforce, Inc CRM $213.65 $342.73 +60% vs FACE
Uber Technologies, Inc UBER $68.59 $101.28 +48% vs FACE
Intuit Inc INTU $341.50 $459.14 +34% vs FACE
ServiceNow, Inc NOW $101.97 $112.17 +10% vs FACE
SAP SE SAP €210.75 €173.59 −18% vs FACE
Cadence Design Systems, Inc CDNS $319.92 $225.48 −30% vs FACE
Automatic Data Processing, Inc ADP $303.35 $150.40 −50% vs FACE
Shopify Inc SHOP $148.91 $64.96 −56% vs FACE
Snowflake Inc SNOW $275.88 $73.81 −73% vs FACE

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Facephi Biometria SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Facephi Biometria SA Fair Value". https://www.fairvalue-calculator.com/stock/FACE

Frequently asked questions

Is Facephi Biometria SA (FACE) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €1.00 versus a price of €1.75, about 43% lower (overvalued).
What is the fair value of FACE?
Our model-based fair value for Facephi Biometria SA is €1.00 (as of Nov 9, 2026), built from audited fundamentals. The current price: €1.75.
What is the quality score of FACE?
Facephi Biometria SA has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Facephi Biometria SA (FACE)?
Our model-based price target is the fair value of €1.00 (as of Nov 9, 2026) from 14 valuation models. Cautious scenario €0.8300, optimistic scenario €1.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Facephi Biometria SA stock forecast for 2026?
Our models put fair value at €1.00, about 43% lower versus a price of €1.75 (overvalued). Cautious scenario €0.8300, optimistic scenario €1.15. The calculation is refreshed regularly with new filings.
What is the revenue of Facephi Biometria SA (FACE)?
Facephi Biometria SA reported trailing-twelve-month revenue of about €40.6M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Facephi Biometria SA (FACE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Facephi Biometria SA it is €1.00 per share (as of Nov 9, 2026), against a price of €1.75. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Facephi Biometria SA stock overvalued or undervalued in 2026?
As of Nov 9, 2026, FACE trades above its calculated fair value: price €1.75, fair value €1.00, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FACE?
No. The price is what the market pays today (€1.75); the fair value is what the company's own numbers justify (€1.00). For Facephi Biometria SA the two are €0.7500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Facephi Biometria SA worth?
The market values Facephi Biometria SA at about €46.3M (market capitalisation, as of Nov 9, 2026). Per share that is €1.75; our models calculate a fair value of €1.00 per share.
What do the bullish and bearish scenarios say about FACE?
Our models span a range for Facephi Biometria SA: cautious scenario €0.8300, base €1.00, optimistic €1.15 per share (as of Nov 9, 2026, price €1.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FACE?
Facephi Biometria SA trades at a price-to-earnings ratio of 125.9 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €1.00 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 16.9 (reported 125.9). Median P/E at fiscal year-end, 5 fiscal years (2017 to 2025), reported earnings, FY2025 ex one-offs: 32.6. Other multiples: PEG 0.1, P/B 2.4, P/S 1.3, EV/EBITDA 23.1.
What is the PEG ratio of FACE?
The PEG ratio of Facephi Biometria SA is 0.10 (P/E divided by earnings growth, as of Nov 9, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Facephi Biometria SA (FACE)?
Balance-sheet figures for Facephi Biometria SA (as of Nov 9, 2026): return on equity 1.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is FACE from its 52-week high?
Facephi Biometria SA trades at €1.75, about 35% below its 52-week high of €2.70 and 24% above the low of €1.42 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €1.00 is for.
Which stocks are comparable to Facephi Biometria SA?
From the same area (Technology) we also value SAP SE, Salesforce, Inc, Shopify Inc, ServiceNow, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Facephi Biometria SA stock attractive at the current price?
The data as of Nov 9, 2026: price €1.75, calculated fair value €1.00 (−43%), Quality Score 40/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FACE calculated?
We run Facephi Biometria SA through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €1.00 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Facephi Biometria SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Facephi Biometria SA (FACE)?
The closing price on Nov 6, 2026 was €1.75. Our model-based fair value is €1.00, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Facephi Biometria SA right now?
The price sits above even our optimistic bull case (€1.15). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Facephi Biometria SA

How large is the market capitalisation of Facephi Biometria SA (FACE)?
The market capitalisation of Facephi Biometria SA is €46.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Facephi Biometria SA (FACE)?
The price-to-sales ratio of Facephi Biometria SA is 0.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Facephi Biometria SA (FACE)?
Earnings per share at Facephi Biometria SA are €0.0139 (price ÷ EPS = P/E 125.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Facephi Biometria SA (FACE)?
The net margin of Facephi Biometria SA is 0.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Facephi Biometria SA (FACE)?
The return on equity (ROE) of Facephi Biometria SA is 1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Facephi Biometria SA (FACE)?
On an EBIT basis the return on assets of Facephi Biometria SA is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Facephi Biometria SA (FACE)?
The operating margin of Facephi Biometria SA is 20.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Facephi Biometria SA (FACE)?
Revenue at Facephi Biometria SA is growing +32.0% versus a year earlier (3y avg +17.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Facephi Biometria SA (FACE)?
Earnings per share at Facephi Biometria SA are growing +12.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Facephi Biometria SA (FACE) generate?
The free cash flow of Facephi Biometria SA is −€1.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Facephi Biometria SA (FACE) carry?
The net debt of Facephi Biometria SA is €5.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Facephi Biometria SA in the live analysis

One click puts Facephi Biometria SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.